Yumanity Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Yumanity Therapeutics Posts Q2 Loss Per Share Of $1.03
Yumanity Therapeutics Inc expected to post a loss of 84 cents a share - Earnings Preview
Yumanity Therapeutics Inc expected to post a loss of 84 cents a share - Earnings Preview
Yumanity Therapeutics Inc expected to post a loss of 84 cents a share - Earnings Preview
Brief: Yumanity Therapeutics Appoints Devin W. Smith As General Counsel
Yumanity Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Yumanity Therapeutics Inc expected to post a loss of 83 cents a share - Earnings Preview
Brief: Yumanity Therapeutics’ YTX-7739 Achieved Target Engagement At Doses That Were Generally Well Tolerated In A Phase 1A Multiple Ascending Dose Study In Healthy Volunteers
Brief: Yumanity Therapeutics Says May Offer And Sell Shares Of Common Stock Having Aggregate Offering Price Of Up To $60 Million From Time To Time
Brief: Yumanity Therapeutics Says YTX-7739 Demonstrates Pre-Clinical Proof Of Concept In Vivo Model
Brief: Yumanity Therapeutics Inc Files For Shelf Of Up To 1.5 Million Shares Of Common Stock By Selling Stockholders - SEC Filing
Brief: Anthony Coles Reports 8.2% Stake In Yumanity Therapeutics
Brief: Proteostasis Stockholders Approve Business Combination With Yumanity Therapeutics
Brief: Yumanity Therapeutics to Raise $33.6 Mln PIPE Contingent on Completion of Reverse Merger with Proteostasis
Brief: Proteostasis Therapeutics Says On November 6, Co And Unit, Yumanity Therapeutics, Yumanity Holdings, Llc Entered Into First Amendment
U.S. RESEARCH ROUNDUP-Netflix, Proteostasis Therapeutics, Zoom Video Communications
Proteostasis Therapeutics: Rises on merger with Yumanity Therapeutics
Brief: Yumanity Therapeutics And Proteostasis Therapeutics Announce Merger Agreement